Aldeyra’s Reproxalap Faces Another FDA Setback: What’s Next for Dry Eye Disease Treatment?
Lexington, Mass. – Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on March 17, 2026, regarding its New Drug Application (NDA) for reproxalap, a potential treatment for dry eye disease. This marks the third time the FDA has rejected the drug, raising questions about the future of this investigational therapy and the broader landscape of dry eye treatments.
The FDA’s Concerns: Efficacy and Consistency
The core of the FDA’s concern, as outlined in the CRL, centers around a lack of “substantial evidence” demonstrating reproxalap’s effectiveness in treating the signs and symptoms of dry eye disease. Specifically, the agency cited “inconsistency of study results” and stated that the “totality of evidence…does not support the effectiveness of the product.” Notably, the FDA did not raise any safety or manufacturing concerns.
This isn’t the first hurdle for reproxalap. Aldeyra initially resubmitted the NDA in October 2024, following a previous Complete Response Letter. The FDA had previously extended the review timeline, with a PDUFA (Prescription Drug User Fee Act) target action date extension announced in December 2025. Label drafts were even exchanged between Aldeyra and the FDA in December 2025 and March 2026, suggesting a degree of progress before the latest rejection.
What Does This Indicate for Patients and the Dry Eye Disease Market?
Dry eye disease affects millions worldwide, and current treatments often provide only modest or delayed relief. Aldeyra’s CEO, Todd C. Brady, emphasized that reproxalap, to their knowledge, is the only drug demonstrating clinical activity within minutes of administration. This potential for rapid relief is a key differentiator, and a significant reason Aldeyra intends to work with the FDA to address their concerns.
Despite the setback, Aldeyra remains optimistic. The FDA has not requested additional clinical trials or confirmatory evidence, instead suggesting exploration into why certain trials failed and identification of specific patient populations where reproxalap might be effective. Aldeyra plans to request a Type A meeting with the FDA within 30 days to discuss the path forward.
Financial Implications and AbbVie’s Role
As of December 31, 2025, Aldeyra reported approximately $70 million in cash reserves, which the company believes is sufficient to fund operations into 2028. This financial cushion provides some runway for further development and engagement with the FDA.
Adding another layer of complexity, AbbVie holds an option agreement for reproxalap. If the FDA approves the drug for dry eye disease, Aldeyra is eligible for a $100 million payment from AbbVie. This potential payout underscores the commercial value AbbVie sees in reproxalap, even in light of the recent CRL.
Looking Ahead: Potential Strategies and Future Research
Aldeyra’s strategy appears to focus on refining its understanding of reproxalap’s efficacy and identifying the patient subgroups most likely to benefit. This could involve further analysis of existing clinical trial data, potentially focusing on specific disease severities or underlying inflammatory profiles.
The FDA’s recommendation to explore specific populations is a common pathway for drug development. Often, a drug that fails to demonstrate broad efficacy can find success within a more targeted patient group. This approach requires careful analysis and potentially biomarker-driven patient selection.
Frequently Asked Questions
- What is a Complete Response Letter (CRL)? A CRL is issued by the FDA when it determines that an NDA is not ready for approval. It outlines the deficiencies that must be addressed before the application can be reconsidered.
- What is reproxalap? Reproxalap is an investigational drug candidate being developed by Aldeyra Therapeutics for the treatment of dry eye disease.
- Does Aldeyra plan to conduct more clinical trials? Currently, Aldeyra does not expect to pursue additional clinical trials, but will request a meeting with the FDA to discuss next steps.
- What is AbbVie’s involvement? AbbVie has an option agreement to acquire reproxalap if it receives FDA approval.
Pro Tip: Keep an eye on Aldeyra’s investor relations website for updates on their meeting with the FDA and any further developments regarding reproxalap.
What are your thoughts on the future of dry eye disease treatments? Share your perspective in the comments below!
